Jagsonpal Pharma to hold 47th AGM on Sep 18, 2026; Record date for Dividend: Sep 04, 2026
Jagsonpal Pharmaceuticals Limited will hold its 47th AGM on September 18, 2026. The record date for dividend is September 04, 2026. The company reported FY26 revenue of ₹287 crore and a 19% growth in Operating PAT to ₹43 crore. It completed a ₹40 crore share buyback and recommended a 200% dividend.
The AGM and dividend announcement are significant for shareholders. The mention of strong financial performance and shareholder returns (buyback, dividend) adds to the impact.
The announcement is primarily procedural, detailing the upcoming AGM and record date for dividend. While financial results are mentioned, the core focus is on the meeting logistics and dividend eligibility, which are neutral events.
Jagsonpal Pharmaceuticals Limited announced the details for its 47th Annual General Meeting (AGM), scheduled to be held on Friday, September 18, 2026, at 03:30 P.M. The meeting will be conducted through Video Conferencing (VC) or Other Audio Visual Means (OAVM), in compliance with directives from the Ministry of Corporate Affairs and SEBI. The Company will dispatch the AGM Notice and the Annual Report for the Financial Year 2025-26 to all registered members. Members holding shares as of the cut-off date, Friday, September 11, 2026, will be eligible to vote. Remote e-voting will commence on Monday, September 14, 2026, at 9:00 A.M. (IST) and conclude on Thursday, September 17, 2026, at 5:00 P.M. (IST). Additionally, the record date for the purpose of ascertaining members eligible for dividend payment has been fixed for Friday, September 04, 2026. The company also reported its financial performance for FY26, with revenue at ₹287 crore, Operating PAT at ₹43 crore (19% growth), and Operating EBITDA at ₹61 crore (21%+ margins). The company also highlighted a ₹40 crore share buyback completed in May 2026 and recommended a 200% dividend, including a 75% special dividend.
What to do with a filing like this
Jagsonpal Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Jagsonpal Pharmaceuticals Limited. Read the original for the full detail.